Literature DB >> 8131381

The use of the DSM-III-R Checklist for initial diagnostic assessments.

J J Hudziak1, J E Helzer, M W Wetzel, K B Kessel, B McGee, A Janca, T Przybeck.   

Abstract

The DSM-III-R Checklist is an efficient method for screening psychiatric patients for major psychiatric disorders while amassing a data base that can be used for later clinical and research activities. It yields valid diagnoses and key adjunctive symptoms. Patients enjoyed the interview, demonstrating an interest in the computer as well as a feeling of confidence in the complete review of symptoms. The psychiatry resident users in this project found the Checklist to be a valuable teaching instrument, a way to develop their thinking about symptoms and diagnostic rules, an efficient means of collecting an automated clinical data base, and a stimulus to pursue further research activities. Finally, the Checklist is an ideal diagnostic tool to amass a research data base and is currently being used in numerous studies by clinicians and nonclinicians.

Entities:  

Mesh:

Year:  1993        PMID: 8131381     DOI: 10.1016/0010-440x(93)90061-8

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  81 in total

1.  Selection of a substance use disorder diagnostic instrument by the National Drug Abuse Treatment Clinical Trials Network.

Authors:  Robert F Forman; Dace Svikis; Ivan D Montoya; Jack Blaine
Journal:  J Subst Abuse Treat       Date:  2004-07

2.  Frontal systems deficits in stimulant-dependent patients: evidence of pre-illness dysfunction and relationship to treatment response.

Authors:  Theresa M Winhusen; Eugene C Somoza; Daniel F Lewis; Frankie B Kropp; Viviana Elizabeth Horigian; Bryon Adinoff
Journal:  Drug Alcohol Depend       Date:  2012-07-06       Impact factor: 4.492

3.  Predictors of 12-Step Attendance and Participation for Individuals With Stimulant Use Disorders.

Authors:  Mary Hatch-Maillette; Elizabeth A Wells; Suzanne R Doyle; Gregory S Brigham; Dennis Daley; Jessica DiCenzo; Dennis Donovan; Sharon Garrett; Viviana E Horigian; Lindsay Jenkins; Therese Killeen; Mandy Owens; Harold I Perl
Journal:  J Subst Abuse Treat       Date:  2016-06-16

4.  Determinants of quality of life in children with psychiatric disorders.

Authors:  Dennis Bastiaansen; Hans M Koot; Robert F Ferdinand
Journal:  Qual Life Res       Date:  2005-08       Impact factor: 4.147

5.  Associations between temperament and DSM-IV externalizing disorders in children and adolescents.

Authors:  David C Rettew; William Copeland; Catherine Stanger; James J Hudziak
Journal:  J Dev Behav Pediatr       Date:  2004-12       Impact factor: 2.225

6.  A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances.

Authors:  R G Vandrey; A J Budney; J R Hughes; A Liguori
Journal:  Drug Alcohol Depend       Date:  2007-07-23       Impact factor: 4.492

7.  Latent class analysis of non-opioid dependent illegal pharmaceutical opioid users in Ohio.

Authors:  Robert G Carlson; Ramzi W Nahhas; Raminta Daniulaityte; Silvia S Martins; Linna Li; Russel Falck
Journal:  Drug Alcohol Depend       Date:  2013-10-23       Impact factor: 4.492

8.  Demand curves for hypothetical cocaine in cocaine-dependent individuals.

Authors:  Natalie R Bruner; Matthew W Johnson
Journal:  Psychopharmacology (Berl)       Date:  2013-11-12       Impact factor: 4.530

9.  Initial feasibility and validity of a prospective memory training program in a substance use treatment population.

Authors:  Mary M Sweeney; Olga Rass; Patrick S Johnson; Eric C Strain; Meredith S Berry; Hoa T Vo; Marc J Fishman; Cynthia A Munro; George W Rebok; Miriam Z Mintzer; Matthew W Johnson
Journal:  Exp Clin Psychopharmacol       Date:  2016-10       Impact factor: 3.157

10.  Marijuana use and intoxication among daily users: an intensive longitudinal study.

Authors:  John R Hughes; James R Fingar; Alan J Budney; Shelly Naud; John E Helzer; Peter W Callas
Journal:  Addict Behav       Date:  2014-06-04       Impact factor: 3.913

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.